Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Sees Large Drop in Short Interest

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) saw a significant decrease in short interest in the month of February. As of February 28th, there was short interest totalling 50,600 shares, a decrease of 29.8% from the February 13th total of 72,100 shares. Currently, 1.8% of the company’s shares are short sold. Based on an average daily trading volume, of 42,500 shares, the days-to-cover ratio is presently 1.2 days.

Kiora Pharmaceuticals Stock Performance

Shares of Kiora Pharmaceuticals stock traded up $0.04 on Tuesday, hitting $3.33. The stock had a trading volume of 586 shares, compared to its average volume of 32,921. The stock has a 50 day moving average of $3.54 and a 200 day moving average of $3.50. Kiora Pharmaceuticals has a twelve month low of $2.91 and a twelve month high of $6.48.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Kiora Pharmaceuticals stock. ADAR1 Capital Management LLC increased its position in Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) by 1.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 200,221 shares of the company’s stock after buying an additional 3,670 shares during the quarter. ADAR1 Capital Management LLC owned 6.67% of Kiora Pharmaceuticals worth $661,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 76.97% of the company’s stock.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.